lung cancer
AstraZeneca’s Imfinzi gets orphan drug designation from FDA
July 12, 2019Medical Communications AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC). The …
NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer
July 5, 2019Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma
NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …
MSD’s Keytruda snatches up first approval in small cell lung cancer
June 19, 2019Research and Development, Sales and Marketing Cancer, FDA, MSD, US, keytruda, lung cancer, pharma
MSD has revealed that its anti-PD-1 immunotherapy Keytruda (pembrolizumab) has been awarded marketing authorisation from the FDA as a monotherapy …
Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer
June 3, 2019Sales and Marketing KEYNOTE, MSD, Merck, keytruda, lung cancer
Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to …
AI better than radiologists at diagnosing lung cancer
May 21, 2019Manufacturing and Production AI, artificial intelligence, cancer screening, lung cancer, pharma ML
An artificial intelligence (AI) is better than specialist doctors at diagnosing lung cancer, according to a study from researchers at …
Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua
May 8, 2019Research and Development Cancer, Europe, Lorviqua, NSCLC, Pfizer, lung cancer, pharma
Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …
FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer
April 12, 2019Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma
MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …
European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer
April 4, 2019Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma
The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …
China approves Keytruda for non-small cell lung cancer
April 2, 2019Manufacturing and Production China, MSD, Merck and Co, USA, keytruda, lung cancer, pharma
US firm MSD has won approval for Keytruda in China. The cancer immunotherapy has thus become the first PD-1 inhibitor …
AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England
March 28, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer
AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …
Roche’s Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer
March 20, 2019Research and Development, Sales and Marketing FDA, Roche, lung cancer, pharma, tecentriq
Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug …
MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer
March 15, 2019Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …
Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment
March 13, 2019Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma
Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …
Roche’s Tecentriq combo scoops up European approval in first-line metastatic lung cancer
March 8, 2019Medical Communications, Sales and Marketing Cancer, Europe, European Commission, NSCLC, Roche, lung cancer, pharma
Roche has announced the approval of the European Commission for its PD-L1 inhibitor Tecentriq (atezolizumab) when used in combination with …
J&J acquires lung cancer-focused robotics firm Auris Health in potential $5.75m deal
February 14, 2019Manufacturing and Production, Research and Development, Sales and Marketing Auris Health, Cancer, J&J, JJ, lung cancer, pharma, robotics
In a bid to bolster its footing in providing surgical treatments, Johnson & Johnson has announced it will acquire robotics …
Latest content
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
